875155-17-2

Upstream product

• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 
• 1357467-09-4 C₈H₃F₄NO₃ 
• 67-56-1 methanol 

Downstream Products

• 950682-76-5 5-morpholin-4-yl-2-nitro-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-30-9 2-nitro-5-thiomorpholin-4-yl-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-33-2 5-azetidin-1-yl-2-nitro-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-51-4 1-(5-methoxycarbonyl-4-nitro-2-trifluoromethyl-phenyl)-1H-imidazole-4-carboxylic acid methyl ester 
• 875155-53-6 5-(4-cyano-imidazol-1-yl)-2-nitro-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-43-4 5-[4-(4-methoxymethyl-phenyl)-imidazol-1-yl]-2-nitro-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-39-8 5-[4-(4-methoxy-phenyl)-imidazol-1-yl]-2-nitro-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-25-2 1-(5-methoxycarbonyl-4-nitro-2-trifluoromethyl-phenyl)-1H-[1,2,4]triazole-3-carboxylic acid ethyl ester 
• 875155-46-7 2-nitro-5-(2-oxo-2H-pyridin-1-yl)-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-36-5 2-nitro-5-(pyridin-3-yloxy)-4-trifluoromethyl-benzoic acid methyl ester 
• 1350742-34-5 2-amino-5-(2-methyl-imidazol-1-yl)-4-trifluoromethyl-benzoic acid methyl ester 
• 1350742-33-4 5-(2-methyl-imidazol-1-yl)-2-nitro-4-trifluoromethyl-benzoic acid methyl ester 

Relevant academic research and scientific papers

2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS

The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists

A new set of quinazolinedione sulfonamide derivatives as competitive AMPA receptor antagonist with improved properties compared to 1 is disclosed. By modulating physico-chemical properties, compound 29 was identified with a low ED50 of 5.5 mg/kg in an animal model of anticonvulsant activity after oral dosage.

QUINAZOLINE DERIVATIVES

The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula (I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.